Seagen Inc.
SGENDrugs in Pipeline
28
Phase 3 Programs
9
Upcoming Catalysts
3
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
Adcetris
Brentuximab Vedotin
Hodgkin Lymphoma
tucatinib
Gastric Adenocarcinoma
doxorubicin
Anaplastic Large-Cell Lymphoma
Trastuzumab
Metastatic Colorectal Adenocarcinoma
brentuximab vedotin
Lymphoma, B-Cell
Padcev
Enfortumab Vedotin
Urothelial Cancer
sigvotatug vedotin
Carcinoma, Non-Small-Cell Lung
gemcitabine
Urothelial Carcinoma
Lenalidomide
Diffuse Large B-cell Lymphoma
disitamab vedotin
Breast Neoplasms
dacarbazine
Hodgkin Disease
nivolumab
Hodgkin Lymphoma
Tisotumab Vedotin (HuMax-TF-ADC)
Ovary Cancer
Lintuzumab (SGN-33)
Acute Myeloid Leukemia
ladiratuzumab vedotin
Triple Negative Breast Neoplasms
SGN-15, Docetaxel
Non-Small Cell Lung Carcinoma
tisotumab vedotin
Ovarian Cancer
SGN-30
Large Cell Lymphoma
carboplatin
Colorectal Neoplasms
SGN-40 (anti-huCD40 mAb)
Leukemia, Lymphocytic, Chronic
Tukysa
Tucatinib
HER2+ Breast Cancer
SGN-40
Lymphoma, Large B-Cell, Diffuse
SGN-30 (monoclonal antibody)
Hodgkin Disease
SGN-15 (cBR96-doxorubicin immunoconjugate)
Prostatic Neoplasms
bendamustine
Hodgkin Disease
SGN-15
Carcinoma, Non-Small-Cell Lung
SGN-30 (anti-CD30 mAb)
Anaplastic Large-Cell Lymphoma
SEA-CD40
Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Adcetris Brentuximab Vedotin | Approved | Hodgkin Lymphoma | Orphan | - |
tucatinib | Phase 3 | Gastric Adenocarcinoma | - | Patent 2038 |
doxorubicin | Phase 3 | Anaplastic Large-Cell Lymphoma | - | - |
Trastuzumab | Phase 3 | Metastatic Colorectal Adenocarcinoma | - | |
brentuximab vedotin | Phase 3 | Lymphoma, B-Cell | - | - |
Padcev Enfortumab Vedotin | Phase 3 | Urothelial Cancer | Fast TrackBreakthrough | - |
sigvotatug vedotin | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
gemcitabine | Phase 3 | Urothelial Carcinoma | - | - |
Lenalidomide | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
disitamab vedotin | Phase 3 | Breast Neoplasms | - | - |
dacarbazine | Phase 2 | Hodgkin Disease | - | |
nivolumab | Phase 2 | Hodgkin Lymphoma | - | - |
Tisotumab Vedotin (HuMax-TF-ADC) | Phase 2 | Ovary Cancer | - | - |
Lintuzumab (SGN-33) | Phase 2 | Acute Myeloid Leukemia | - | - |
ladiratuzumab vedotin | Phase 2 | Triple Negative Breast Neoplasms | - | - |
SGN-15, Docetaxel | Phase 2 | Non-Small Cell Lung Carcinoma | - | Patent 2036 |
tisotumab vedotin | Phase 2 | Ovarian Cancer | - | - |
SGN-30 | Phase 2 | Large Cell Lymphoma | - | - |
carboplatin | Phase 2 | Colorectal Neoplasms | - | - |
SGN-40 (anti-huCD40 mAb) | Phase 2 | Leukemia, Lymphocytic, Chronic | - | - |
Tukysa Tucatinib | Phase 2 | HER2+ Breast Cancer | Fast TrackBreakthrough | Patent 2038 |
SGN-40 | Phase 2 | Lymphoma, Large B-Cell, Diffuse | - | - |
SGN-30 (monoclonal antibody) | Phase 2 | Hodgkin Disease | - | - |
SGN-15 (cBR96-doxorubicin immunoconjugate) | Phase 2 | Prostatic Neoplasms | - | - |
bendamustine | Phase 2 | Hodgkin Disease | - | - |
SGN-15 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
SGN-30 (anti-CD30 mAb) | Phase 2 | Anaplastic Large-Cell Lymphoma | - | - |
SEA-CD40 | Phase 2 | Melanoma | - | - |
Hodgkin Disease
3 drugs in this indication
Hodgkin Lymphoma
2 drugs in this indication
Anaplastic Large-Cell Lymphoma
2 drugs in this indication
HER2+ Breast Cancer
1 drug in this indication
Triple Negative Breast Neoplasms
1 drug in this indication
Leukemia, Lymphocytic, Chronic
1 drug in this indication
Lymphoma, Large B-Cell, Diffuse
1 drug in this indication
Prostatic Neoplasms
1 drug in this indication
Metastatic Colorectal Adenocarcinoma
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Gastric Adenocarcinoma
1 drug in this indication
Large Cell Lymphoma
1 drug in this indication
Lymphoma, B-Cell
1 drug in this indication
Ovary Cancer
1 drug in this indication
Non-Small Cell Lung Carcinoma
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Melanoma
1 drug in this indication
Acute Myeloid Leukemia
1 drug in this indication
Disease, Hodgkin
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Seagen Inc.'s drug pipeline?→
CatalystAlert tracks 28 drug candidates in Seagen Inc.'s (SGEN) pipeline across Phase 3, Phase 2, Approved. Its lead program is tucatinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Seagen Inc.'s next FDA catalyst?→
Seagen Inc.'s (SGEN) next tracked catalyst is a Phase 2 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SGEN biotech catalysts?→
Add SGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Seagen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.